In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Gritstone gets $21mm through Series C ahead of IPO

Executive Summary

Gritstone Oncology Inc. (cancer immunotherapies) raised $21mm through its Series C round, including a $10mm investment from new partner bluebird bio. The companies penned a deal potentially worth up to $1.2bn for Gritstone, through which the company will use its EDGE neoantigen platform to help bluebird discover and develop new cell therapies. The alliance and Series C round were announced in tandem with Gritstone's filing for its initial public offering.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register